Lijuan Zeng, Jamie Perin, Alden L Gross, David Shade, Krista L Lanctôt, Alan J Lerner, Jacobo E Mintzer, Olga Brawman-Mintzer, Prasad R Padala, Christopher H van Dyck, Anton P Porsteinsson, Suzanne Craft, Allan Levey, Nathan Herrmann, Paul B Rosenberg
OBJECTIVES: To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia. METHODS: The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months...
June 2024: International Journal of Geriatric Psychiatry